NAFLD & NASH. Naga Chalasani, MD, FACG Professor of Medicine and Cellular & Integrative Physiology Director, Division of GI and Hepatology
|
|
- Jason Hubbard
- 6 years ago
- Views:
Transcription
1 NAFLD & NASH Naga Chalasani, MD, FACG Professor of Medicine and Cellular & Integrative Physiology Director, Division of GI and Hepatology Indiana University School of Medicine ACG Midwest Regional Course, Indianapolis Potential Conflicts Conflicts related to NAFLD Amylin Conflicts related to DILI Salix, Vertex, Merck, Sanofi, GSK, Lilly, Mochida Research Support Amylin, Intercept, Lilly, GenFit, Takeda August
2 Outline Background and Definitions Risk Factors Natural History Diagnosis Treatment Will not discuss pathogenesis, animal models, or newer GWAS data NAFLD NAFLD is present in 30% US adults and 10-15% children Most common cause of elevated liver enzymes in both adults and children Up to 5% US adults may have NASH It may account for up to 80% of cryptogenic cirrhosis August
3 Spectrum of NAFLD: NAFL vs. NASH Simple fatty liver is histologically characterized by macrovesicular steatosis with no additional pathology. Fatty liver is generally considered benign from a hepatic standpoint. NASH is histologically advanced fatty liver. It is characterized dby steatosis, inflammation, i ballooning, and fibrosis. It can lead to cirrhosis and liver failure. Spectrum of NAFLD Normal Steatosis (NAFL) Steatohepatitis (NASH) Fibrosis/ cirrhosis August
4 Risk Factors for NAFLD Major Co-morbidities Type2 Diabetes Dyslipidemia Obesity Metabolic Syndrome Emerging Associations Hypothyroidism Sleep Apnea Hypopituitarism Hypogonadism Polycystic Ovary Syndrome Lonardo A, et al. J Hepatol 2006; 44: McCullough A et al. J Clin Gastroenterol 2002;34: Hepatic Outcomes of NAFLD Simple steatosis is largely benign with minimal risk of cirrhosis NASH is progressive with 20% risk of cirrhosis over a 10-yr time horizon NASH cirrhosis is at moderate risk for HCC (2-4% per year) Cryptogenic cirrhosis is likely a burnt-out form of NASH in up to 80% of patients Post-transplant transplant recurrence may occur August
5 Outcomes in NAFLD Surrogates # Studies OR [95% CI] Overall NAFLD vs. General 8studies 1.57 [ ] Mortality Population Incident CVD ALT as a surrogate GGT as a surrogate Imaging as a surrogate 6 studies 10 studies 7 studies 1.10 [ ] 1.57 [ ] 2.05 [ ] Incident ALT as a surrogate 17 studies 1.97 [ ] type2 DM GGT as a surrogate Imaging as a surrogate 12 studies 3 studies 2.74 [ ] 3.51 [ ] Musso G et al. Annals of Medicine 2011 NASH Vs. Steatosis Outcomes # studies OR [95% CI] Overall Mortality 5 studies 1.81 [ ] Liver-related Mortality 5 studies 5.71 [ ] CVD related Mortality 5 Studies 0.01 [ ] Musso G et al. Annals of Medicine 2011 August
6 Work up of patients with NAFLD Imaging to establish the presence of steatosis Meticulous alcohol and medication history Exclusion of co-existing or competing etiologies Auto-antibodies and hyperferritinemia are common Fasting lipid profile and measures of insulin resistance Liver biopsy to establish the presence of NASH When to biopsy? Chalasani N, et al. The diagnosis and management of nonalcoholic fatty liver disease. AASLD, AGA, ACG Practice Guideline. Gastroenterology, Hepatology, AJG 2012 August
7 Surrogate Markers/Predictive Models Predict NASH Metabolic Syndrome CK-18 fragments CK-18 + sfas Oxidized Fatty acids NASH test NASH Predictive Index Obesity NAFLD score NASH Clinical Score NAFIC (ferritin, insulin, collagen) Predict advanced fibrosis Fibrotest NAFLD Fibrosis Score BARD score ELF Fibrometer OWL Genomics IU panel Transient elastography MR elastography Musso G et al. Annals of Medicine 2011 CK-18 fragments Circulating CK-18 fragment levels are elevated in NASH patients 10 studies (adult and pediatric studies) Various cut-off values, range U/L Summary estimates: AUC [95% CI]: 0.82 [ ] 0.88] Median Sensitivity: 78% Median Specificity: 87% Musso G et al. Annals of Medicine 2011 August
8 Selected Fibrosis Models # studies AUC [95% CI] Sens Spec Fibrotest 2 studies F [ ] 76% 74% NAFLD Fibrosis Score BARD Score 13 studies F [ ] Cut-off studies F [ ] Cut-off 2 90% 60% % 97% 72% 64% ELF 1 study Any 0.76 [ ] 61% 80% fibrosis F [ ] 70% 80% F [ ] 80% 90% Fibrotest: α2 macroglobulin, ApoA, haptoglobin, GGT, Total Bilirubin NAFLD Fibrosis Score: Age, BMI, Diabetes, AST/ALT ratio, albumin, Platelets BARD score: BMI > 28, AST/ALT ratio > 0.8, Diabetes ELF: Hyaluronic acid, PIIINP, TIMP NAFLD Fibrosis Score patients, 480 estimation group, 253 validation group [US, UK, and Australia] Independent predictors of advanced (bridging or cirrhosis) fibrosis: Age BMI AST/ALT ratio Hyperglycaemia (FBG >6.1mmol/l or diabetes) Platelet count Albumin Angulo et al Hepatology 2007 August
9 The ELF score Age, HA, PIIIP, TIMP Derived in400 test cases, validated in 521 Rosenberg, Burt Gastroenterology How to treat a patient with NAFLD? If a patient has NASH, then attention should be paid to both metabolic co-morbidities as well as liver disease However, if a patient has steatosis alone, then attention should be paid to metabolic and cardiovascular morbidities. August
10 Treatment of liver disease in NAFLD Potential Options Life style modification Insulin sensitizers Vitamin E Bariatric surgery Tested but do not work: UDCA, Metformin Under investigation: Pentoxifylline, Obeticholic acid, Eicosapentanoic acid, and many others Ongoing Phase 3 programs Intercept 747 (Obeticholic acid) FXR agonist Phase 3 study through NASH CRN EDA-E E (Ethyl Icosapentate) Phase 3, multicenter study (Medpace/Fulcrum/Mochida) Combined PPARα/δ agonist (GenFit) Combined pioglitazone/roflumilast (Takeda) August
11 Lifestyle Modification Weight loss, either by hypocaloric diet alone or in conjunction with exercise, reduces hepatic steatosis Weight loss ~ 5% of body weight is necessary for improving in steatosis Weight loss ~ 7-10% of body weight is necessary for improving in necroinflammation No data available on specific diets Weight loss: Bariatric surgery Bariatric surgery improves steatosis and may improve necroinflammation i (and possibly fibrosis) in carefully selected patients Meta-analysis analysis by Mummadi et al. showed that steatosis, steatohepatitis, and fibrosis appear to improve following bariatric surgery However, Cochrane review highlights lack of well designed studies Mummadi RR et al. Clinical Gastro Hepatol 2008 Chavez-Tapia NC, et al. Cochrane Database of Systematic Reviews 2010 August
12 Significant Improvement in histology following bariatric surgery 1 st biopsy 2 nd biopsy at 13 months Mattar SG et al. Annals of Surgery 2005; 242: Significant Improvement in histology following bariatric surgery 1 st biopsy 2 nd biopsy at 8.5 months Mattar SG et al. Annals of Surgery 2005; 242: August
13 Significant Improvement in Fibrosis Bariatric Surgery for NASH Bariatric surgery specifically to treat NASH is premature at this time NASH would greatly respond to foregut bariatric surgery It can be performed even in compensated cirrhotics as long as portal hypertension is absent (no varices and no intra-abdominal abdominal collaterals by imaging) August
14 Insulin Sensitizers Metformin No role in either adults or children TZDs improve liver histology but weight gain is a problem. Rosiglitazone is essentially unavailable Role of pioglitazone is unclear improves histology in non-diabetics with NASH, but it is not approved in non-diabetics. Accumulating evidence for unfavorable safety profile. n TZDs for NASH Agent Dose Tetri 30 Rosi 8 mg Sanyal 21 Pio 30 mg Belfort 55 Pio 45 mg Duration Enzymes Histology 48 weeks Improved Improved steatosis, Inflammation, and fibrosis 6 months N/A Improved steatosis, Inflammation 6 months Improved Improved steatosis, Inflammation Ratziu 63 Rosi (8 mg) 12 months Improved Improved steatosis Aithal 74 Pio 30 mg 12 months Improved Improved Steatos, inflammation and fibrosis PIVENS 247 Pio 30 mg 24 months Improved Improved steatosis, inflammation and ballooning August
15 AASLD/AGA/ACG Practice Guideline Vitamin E: PIVENS trial Multicenter RCT, 247 patients, Placebo vs. vit E (800 iu/d) vs. pioglitazone (30 mg/d), 96 weeks Histology primary end point Compared to placebo (19%), significantly greater proportion of patients in vitamin E group (43%) met the primary end point (p<0.01, NNT:4.4) 4) TONIC trial in children also showed histological improvement with vitamin E Sanyal AJ, et al. N Engl J Med 2010; 362: Lavine JE, et al. JAMA 2011 August
16 AASLD/AGA/ACG Practice Guideline Alcohol use in patients with NAFLD and NASH While heavy drinking is certainly deleterious, there are evolving data to suggest non-heavy drinking may have hepatic and metabolic benefits. August
17 Cardiovascular disease in NAFLD Heavily enriched with cardiovascular risk factors Increased prevalence of surrogate markers of coronary artery disease Many studies have shown cardiovascular disease as the single most common cause of death in patients with NAFLD General guidelines for managing cardiovascular risk in NAFLD A diet low in sodium and simple sugars, with substitution btitti of unsaturated tdftf fat for saturated tdand trans-fats, and increased consumption of fruits and vegetables. Consumption of food products enriched omega3 fatty acids Caloric restriction to achieve and maintain ideal body weight. Moderate to vigorous exercise for 30 min to 60 minutes per day most days of the week Smoking cessation & avoidance of alcohol August
18 Statins can be used safely in patients with fatty liver Patients with NAFLD are important targets for statins Risk of serious hepatotoxicity from statins is very rare Patients with underlying liver disease are not at higher risk for statin hepatotoxicity Case series have shown histological improvement in NASH Fish oil is probably the first choice to treat hypertriglyceridemia Chalasani N. Hepatology 2005; 41: ; Hepatology. 2007;46: All patients with NAFLD Patients with NASH COMMENTS Weight Loss Yes Yes 5% Weight loss for improving steatosis & 7-10% weight loss is needed for improving necro-inflammation. Management of Yes, as appropriate p Yes, as Fish oil is the first line medication for Dyslipidemia appropriate hypertriglyceridemia & Statins are the treatment of choice for improving LDL-Cholesterol Insulin resistance and diabetes Bariatric Surgery Yes, as appropriate Yes, as appropriate Metformin improves insulin resistance but has no effect on liver histology. Will help steatosis and necroinflammation if performed for other indications. Should not be performed to specifically treat NASH. Should not be performed in those varices. Vitamin E No Yes Recent SELECT study showed increased risk of prostate cancer. Pioglitazone No Yes Weight gain, CHF, bone loss, and bladder cancer (very rarely) August
19 Take Home Messages Exclude competing etiologies and look for coexisting liver diseases Steatosis t is hepatically benign but NASH is progressive and can lead to cirrhosis Patients with NAFLD are at higher risk for incident type2 diabetes and cardiovascular disease Liver biopsy can establish the diagnosis of NASH Management of NAFLD include managing underlying metabolic and cardiovascular risks as well as managing liver disease Referrals for Clinical Trials Naga Chalasani (Office) (Cell) nchalasa@iupui.edu hl i d August
Non-Alcoholic Steatohepatitis (NASH): What the Gastroenterologist Should Know
Non-Alcoholic Steatohepatitis (NASH): What the Gastroenterologist Should Know Naga P. Chalasani, MD, FACG Professor of Medicine and Cellular & Integrative Physiology Director, Division of GI and Hepatology
More informationWhat is NAFLD?.NASH? Presenter Disclosure Information. Learning Objectives. Case 1: Rob. Questions Pertinent to Rob
Presenter Disclosure Information 5 6pm Nonalcoholic Fatty Liver Disease (NAFLD): Another Obesity-Related Epidemic SPEAKER Elliot Tapper, MD The following relationships exist related to this presentation:
More informationNAFLD: ACG Southern Regional Course Nashville, TN. Speaking - None
NAFLD: 2015 Naga Chalasani, MD, FACG David W. Crabb Professor of Medicine Director, Division of GI and Hepatology Indiana University School of Medicine ACG Southern Regional Course Nashville, TN Disclosures
More informationNON-ALCOHOLIC FATTY LIVER DISEASE:
NON-ALCOHOLIC FATTY LIVER DISEASE: ROLE OF THE PRIMARY PROVIDER Archita P. Desai, MD Assistant Professor of Medicine University of Arizona 25 th Annual Southwestern Conference on Medicine Outline Pathophysiology
More informationPEDIATRIC FOIE GRAS: NON-ALCOHOLIC FATTY LIVER DISEASE
PEDIATRIC FOIE GRAS: NON-ALCOHOLIC FATTY LIVER DISEASE Updates on New insights into NAFLD and NASH pathophysiology New AASLD/AGA/ACG guidelines for NAFLD and NASH, as pertains to pediatrics Evidence-based
More informationNon-Alcoholic Fatty Liver Disease
Non-Alcoholic Fatty Liver Disease None Disclosures Arslan Kahloon M.D Chief, Division of Gastroenterology and Hepatology University of Tennessee College of Medicine Chattanooga Objectives Understand the
More informationLavine, MD, PhD; 4 Anna Mae Diehl, MD; 5 Elizabeth M. Brunt, MD; 6 Kenneth Cusi, MD; 7 Michael Charlton, MD; 8 Arun J. Sanyal, MD
Page 1 of 59 The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and
More informationNONALCOHOLIC FATTY LIVER DISEASE. Non-Alcoholic Fatty Liver Disease (NAFLD) Primary NAFLD. April 13, 2012
NONALCOHOLIC FATTY LIVER DISEASE Kiran Bambha, MD University of Colorado Denver April 13, 2012 Non-Alcoholic Fatty Liver Disease (NAFLD) Primary NAFLD Simple Steatosis Fatty hepatocytes Intracellular fat
More informationNONALCOHOLIC FATTY LIVER DISEASE
NONALCOHOLIC FATTY LIVER DISEASE Kiran Bambha, MD, MSc Hepatology and Liver Transplantation University of Colorado Denver April 13, 2012 Non-Alcoholic Fatty Liver Disease (NAFLD) Terminology Pathogenesis
More informationFatty Liver Disease. Mark Thursz. Imperial College
Fatty Liver Disease Mark Thursz Imperial College Non-Alcoholic Fatty Liver Disease UK adult obesity (BMI>30) 1980: 6% [M], 8% [F]. 1997: 17% [M], 20% [F]. By 2004, 23.6% of men and 23.8% of women were
More informationAt Least 1 in 5 Patients in Your Practice Have Fatty Liver
At Least 1 in 5 Patients in Your Practice Have Fatty Liver What Can You Tell Your Patients Magnus McLeod MD FRCPC Assistant Professor Dalhousie University 30-NOV-2017 NAFLD Non-Alcoholic Fatty Liver Disease
More informationNAFLD: evidence-based management. Curso de residentes AEEH Salvador Augustin, MD Liver Unit Vall d Hebron Hospital Barcelona, Spain
NAFLD: evidence-based management Curso de residentes AEEH 2017 Salvador Augustin, MD Liver Unit Vall d Hebron Hospital Barcelona, Spain Clinical case - 55 yo female - Sent for incidental steatosis at abdominal
More informationUpdate on Non-Alcoholic Fatty Liver Disease. Timothy R. Morgan, MD Chief, Hepatology, VA Long Beach Professor of Medicine, UCI
Update on Non-Alcoholic Fatty Liver Disease Timothy R. Morgan, MD Chief, Hepatology, VA Long Beach Professor of Medicine, UCI February 3, 2018 Disclosure Clinical trials: Genfit Speaker s Bureau: none
More informationNAFLD: US GUIDELINES. US Guidelines for NAFLD
NAFLD: US GUIDELINES Arun J Sanyal M.D. Charles Caravati Professor of Medicine Virginia Commonwealth University School of Medicine US Guidelines for NAFLD Represents consensus amongst AGA, AASLD and ACG
More informationNormal ALT for men 30 IU/L 36% US males abnormal. Abnl ALT. Assess alcohol use/meds. Recheck in 6-8 weeks. still pos
Fatty liver disease Its not just for big boys anymore Ken Flora, MD, FAASLD, FACG, AGAF No disclosures Common situation Normal ALT for men 30 IU/L 36% US males abnormal Normal ALT for women 20 IU/L 28%
More informationUpdate on Nonalcoholic Fatty Liver Disease. Kathleen E Corey, MD, MPH, MMSc Director, Mass General Fatty Liver Clinic
Update on Nonalcoholic Fatty Liver Disease Kathleen E Corey, MD, MPH, MMSc Director, Mass General Fatty Liver Clinic Outline Defining the phenotypes of nonalcoholic fatty liver disease NAFLD Diagnostics
More informationNON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) NON-ALCOHOLIC STEATOHEPATITIS (NASH) ADDRESSING A GROWING SILENT EPIDEMIC
NON-ALCOHOLIC FATTY LIVER DISEASE () & NON-ALCOHOLIC STEATOHEPATITIS () ADDRESSING A GROWING SILENT EPIDEMIC PREVALENCE OF / USA Prevalence in Middle Age Patients San Antonio, Texas (Williams et al., Gastroenterology
More informationPREVALENCE OF NAFLD & NASH
- - PREVALENCE OF & USA Prevalence in Middle Age Patients San Antonio, Texas (Williams et al., Gastroenterology 2011; 140:124-31) Dallas Heart Study Prevalence Numbers (Browning et al., Hepatology 2004;40:1387-95)
More informationNonalcoholic Fatty Liver Disease in Children: Typical and Atypical
Nonalcoholic Fatty Liver Disease in Children: Typical and Atypical Disclosure Naim Alkhouri, MD discloses the following relationships with commercial companies: Membership in the Speakers Bureau for Alexion
More informationNON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) NON-ALCOHOLIC STEATOHEPATITIS (NASH) ADDRESSING A GROWING SILENT EPIDEMIC
NON-ALCOHOLIC FATTY LIVER DISEASE () & NON-ALCOHOLIC STEATOHEPATITIS () ADDRESSING A GROWING SILENT EPIDEMIC PREVALENCE OF / USA Prevalence in Middle Age Patients San Antonio, Texas (Williams et al., Gastroenterology
More informationFatty Liver Disease A growing epidemic
Fatty Liver Disease A growing epidemic Updates in GIM for Primary Care Don C. Rockey March 9 th, 2018 Disclosures 2018 Research Funding (all to MUSC) NIH/NIDDK Actelion Pharmaceuticals Gilead Sciences
More informationThe Skinny On Non Alcoholic Fatty Liver Disease
The Skinny On Non Alcoholic Fatty Liver Disease UCSF Advances in Internal Medicine Monika Sarkar, MD, MAS UCSF Division of GI/Hepatology June 24th, 2015 Non Alcoholic Fatty Liver Disease: Outline Pathogenesis
More informationFatty liver disease: What do we know?
Fatty liver disease: What do we know? Prof. Dr. Claus Niederau Katholische Kliniken Oberhausen ggmbh St. Josef-Hospital Academic Teaching Hospital University of Duisburg-Essen NAFLD Non-Alcoholic Fatty
More informationNAFLD & NASH: Russian perspective
NAFLD & NASH: Russian perspective Vasily Isakov, MD, PhD Professor, Chief, Department Gastroenterology & Hepatology, Federal Research Center of nutrition, biotechnology and food safety Disclosures Received
More informationWHAT CAN YOU USE IN YOUR CLINIC TODAY FOR THE TREATMENT OF NASH?
WHAT CAN YOU USE IN YOUR CLINIC TODAY FOR THE TREATMENT OF NASH? Helena Cortez-Pinto Laboratório de Nutrição, FML, Serviço de Gastrenterologia, Hospital St Maria, Lisboa, Portugal EASL Governing Board:
More informationtage Percent Total & over Total & over Men Women Men Women
Paul Angulo, MD, FACG, AGAF Professor of Medicine, Section Chief of Hepatology Division i i of Digestive i Diseases and Nutrition i University of Kentucky Medical Center Lexington, KY Paul Angulo, MD University
More informationFATTY LIVER DISEASE (NAFLD) (NASH) A GROWING
NON ALCOHOLIC FATTY LIVER DISEASE () & NON ALCOHOLIC S T E ATO H E PAT I T I S () ADDRESSING A GROWING SILENT EPIDEMIC Prevalence of & USA Prevalence in Middle Age Patients San Antonio, Texas (Williams
More informationEASL-EASD-EASO Clinical Practice Guidelines for the management and treatment of NAFLD. Francesco Negro University of Geneva - Switzerland
EASL-EASD-EASO Clinical Practice Guidelines for the management and treatment of NAFLD Francesco Negro University of Geneva - Switzerland EASL EASD - EASO G Marchesini CP Day J-F Dufour A Canbay V Nobili
More informationEarly life determinants of Non-Alcoholic Fatty Liver Disease and NASH DR JULIANA MUIVA-GITOBU KENYA PAEDIATRIC ASSOCIATION CONFERENCE APRIL 2016.
Early life determinants of Non-Alcoholic Fatty Liver Disease and NASH DR JULIANA MUIVA-GITOBU KENYA PAEDIATRIC ASSOCIATION CONFERENCE APRIL 2016. Outline Definition NAFLD and NASH Magnitude of the problem
More informationAAIM: GI Workshop Follow Up to Case Studies. Non-alcoholic Fatty Liver Disease Ulcerative Colitis Crohn s Disease
AAIM: GI Workshop Follow Up to Case Studies Non-alcoholic Fatty Liver Disease Ulcerative Colitis Crohn s Disease Daniel Zimmerman, MD VP and Medical Director, RGA Global October 2015 Non-alcoholic Fatty
More informationPrognosis of NASH VII Workshop Intenracional de Actualizaçao em Hepatologia, Aug 29th 2014
Prognosis of NASH VII Workshop Intenracional de Actualizaçao em Hepatologia, Aug 29th 2014 Vlad Ratziu, Université Pierre et Marie Curie, Hôpital Pitié Salpêtrière, Paris, France NASH : a severe hepatic
More informationImproving Access to Quality Medical Care Webinar Series
Improving Access to Quality Medical Care Webinar Series Presented by The Arizona Telemedicine Program and the Southwest Telehealth Resource Center 2015 UA Board of Regents Welcome AZ, UT, CO, NM & NV FLEX
More informationEVALUATION OF ABNORMAL LIVER TESTS
EVALUATION OF ABNORMAL LIVER TESTS MIA MANABAT DO PGY6 MOA 119 TH ANNUAL SPRING SCIENTIFIC CONVENTION MAY 19, 2018 EVALUATION OF ABNORMAL LIVER TESTS Review of liver enzymes vs liver function tests Clinical
More informationNASH UPDATE ON DIAGNOSTICS AND THERAPY. Arun J Sanyal MBBS, MD Virginia Commonwealth University School of Medicine
NASH UPDATE ON DIAGNOSTICS AND THERAPY Arun J Sanyal MBBS, MD Virginia Commonwealth University School of Medicine Conflicts of interest Salaried employee: of VCU Member of Board: McGuire VA Research Institute,
More informationWhat to do about the high ALT picked up at the annual review. Dr Michael Yee Consultant in Diabetes and Endocrinology
What to do about the high ALT picked up at the annual review Dr Michael Yee Consultant in Diabetes and Endocrinology Mrs DC HPC PMH Type 2 Diabetes (decades) Regular retinal screening No foot complications/neuropathy
More informationNonalcoholic Fatty Liver Disease: Definitions, Risk Factors, and Workup
REVIEW REVIEW Nonalcoholic Fatty Liver Disease: Definitions, Risk Factors, and Workup Puneet Puri, M.B.B.S., M.D. and Arun J. Sanyal, M.B.B.S., M.D. Nonalcoholic fatty liver disease (NAFLD) is defined
More informationUpdate on Clinical Management
Non-Alcoholic Fatty Liver Disease Update on Clinical Management Lisa J. Yoo, D.O. Gastroenterologist Regional Gastroenterology INTRODUCTION Non-alcoholic fatty liver disease (NAFLD) is characterized by
More informationNASH : Diagnosis and investigation. VII Workshop international, Curitiba, Brazil 29/08/2014
NASH : Diagnosis and investigation VII Workshop international, Curitiba, Brazil 29/08/2014 Vlad Ratziu, Université Pierre et Marie Curie, Hôpital Pitié Salpêtrière, Paris, France Usual diagnostic circumstances
More information6/28/2017. Update in NAFLD. Key Points. NAFLD: Epidemiology. US Population: million. NALFD Prevalence 25% 80 million
Update in NAFLD PHILLIP K HENDERSON, DO ASSISTANT PROFESSOR OF MEDICINE UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE INSTRUCTOR OF SURGERY, DIVISION OF TRANSPLANT SURGERY UNIVERSITY OF ALABAMA AT BIRMINGHAM
More informationNAFLD/NASH. Definitions. Pathology NASH. Vicki Shah PA-C, MMS Rush University Hepatology
NAFLD/NASH Vicki Shah PA-C, MMS Rush University Hepatology Definitions NAFLD Evidence of hepatic steatosis by histology (5%) or imaging No causes for secondary fat accumulation EtOH, Drugs, hereditary
More informationDisclosure. Objectives. Smash the Nash: A practical approach to fatty liver disease
Smash the Nash: A practical approach to fatty liver disease Bruce D. Askey, MS, ANP-BC Associate Lecturer North Andover, MA Adult Nurse Practitioner Dept. of Hepatology/Gastroenterology Guthrie Clinic
More informationCDHNF & NASPGHAN A Partnership for Research and Education for Children s Digestive and Nutritional Health
CDHNF & NASPGHAN A Partnership for Research and Education for Children s Digestive and Nutritional Health Obesity and NAFLD Definitions: Nonalcoholic steatohepatitis (NASH) and nonalcoholic fatty liver
More informationInvestigating general liver disease/transaminitis
BHIVA Autumn Conference London 14 October 2016 Investigating general liver disease/transaminitis Emmanuel A. Tsochatzis Senior Clinical Lecturer and Consultant Hepatologist Institute for Liver and Digestive
More informationInternal Medicine Grand Rounds University of Texas Southwestern Medical Center October 5, 2018
Internal Medicine Grand Rounds University of Texas Southwestern Medical Center October 5, 2018 Nonalcoholic Fatty Liver Disease (NAFLD) Turns 38-What Have We Learned? Jay D. Horton, M.D. This is to acknowledge
More informationNAFLD 2017 Identifying and managing disease while waiting for a cure
NAFLD 2017 Identifying and managing disease while waiting for a cure A. Sidney Barritt IV, MD, MSCR Associate Professor of Medicine UNC Liver Center High Impact Hepatology 4 November 2017 Disclosures I
More informationFirst European NAFLD-NASH Summit European Parliament, Brussels, May 31 st NAFLD/NASH : an expanding burden on liver health
First European NAFLD-NASH Summit European Parliament, Brussels, May 31 st 2017 NAFLD/NASH : an expanding burden on liver health Vlad Ratziu, Université Pierre et Marie Curie, Hôpital Pitié Salpêtrière,
More informationNon-Alcoholic Fatty Liver Disease
Non-Alcoholic Fatty Liver Disease Varun Saxena, MD MAS Gastroenterology and Hepatology Kaiser Permanente South San Francisco Assistant Clinical Professor University of California San Francisco January
More informationFatty Liver in HIV. Richard K. Sterling, MD, MSc, FACP, FACG
Fatty Liver in HIV Richard K. Sterling, MD, MSc, FACP, FACG Professor of Medicine Chief, Section of Hepatology Director, HIV-Liver Disease Virginia Commonwealth University Liver-Related Deaths in HIV 1246
More informationFATTY LIVER WHAT YOU NEED TO KNOW AND WHEN TO WORRY JOHN IGOE MD GASTROENTEROLOGY NBIMU APRIL 28 TH 2017
FATTY LIVER WHAT YOU NEED TO KNOW AND WHEN TO WORRY JOHN IGOE MD GASTROENTEROLOGY NBIMU APRIL 28 TH 2017 CONFLICT OF INTEREST AND DISCLOSURES Financial Interest or Affiliation Commercial Enterprise(s)
More informationABNORMAL LIVER FUNCTION TESTS. Dr Uthayanan Chelvaratnam Hepatology Consultant North Bristol NHS Trust
ABNORMAL LIVER FUNCTION TESTS Dr Uthayanan Chelvaratnam Hepatology Consultant North Bristol NHS Trust INTRODUCTION Liver function tests Cases Non invasive fibrosis measurement Questions UK MORTALITY RATE
More informationDisclosures. The Typical Therapeutic Pyramid $$$ The NAFLD Umbrella. The Big Question: What are the treatment options for NASH?
Disclosures I have the following relationships to disclose: Ethicon Endo Surgery Inc. Galectin Therapeutics Synageva Biopharma Raptor Pharmaceuticals I will be discussing off label use of medications in
More informationNon-Alcoholic Fatty Liver Diseasean underestimated epidemic
Non-Alcoholic Fatty Liver Diseasean underestimated epidemic Amir Shlomai MD,PhD Head, Department of Medicine D The Liver Institute Rabin Medical Center, Beilinson Hospital The IASLD semi-annual meeting-
More informationFatty Liver, NASH: new diagnostics and new treatments
Fatty Liver, NASH: new diagnostics and new treatments Robert G Gish MD Professor Consultant Stanford University HASLD TP HCMC June 2016 NAFLD: the hepatic manifestation of the metabolic syndrome Obesity
More informationNon-alcoholic fatty liver disease: time to take note and manage. Philip Newsome Professor of Hepatology & Director of Centre for Liver Research
Non-alcoholic fatty liver disease: time to take note and manage Philip Newsome Professor of Hepatology & Director of Centre for Liver Research Disclosures Consultancy, Co-ordinating Investigator roles
More informationThe role of non-invasivemethods in evaluating liver fibrosis of patients with non-alcoholic steatohepatitis
The role of non-invasivemethods in evaluating liver fibrosis of patients with non-alcoholic steatohepatitis Objectives: Liver biopsy is the gold standard for diagnosing the extent of fibrosis in NAFLD/NASH;
More informationLaboratory analysis of the obese child recommendations and discussion. MacKenzi Hillard May 4, 2011
Laboratory analysis of the obese child recommendations and discussion MacKenzi Hillard May 4, 2011 aka: What to do with Fasting Labs The Obesity Epidemic The prevalence of obesity in adolescents has tripled
More informationLiver Pathology in the 0bese
Liver Pathology in the 0bese Rob Goldin Centre for Pathology, Imperial College r.goldin@imperial.ac.uk Ludwig et al. Non-alcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease.
More informationNew targets for the treatment of NASH (NAFLD) in 2012?
New targets for the treatment of NASH (NAFLD) in 2012? Dominique Larrey Service d Hépatogastroenterologie et transplantation Hôpital Saint Eloi CHU Montpellier INSERM 1040-IRB France Dom-larrey@chu-montpellier.fr
More informationNon alcoholic fatty liver disease and atherosclerosis Raul Santos, MD
Non alcoholic fatty liver disease and atherosclerosis Raul Santos, MD Sao Paulo Medical School Hospital Sao Paulo, Brazil Disclosure Honoraria received for consult and/or speaker : Astra Zeneca, Amgen,
More informationBiopsies. macrovesicular steatosis (zone III) Criteria for Dx of NASH. Liver Ultrasound Report. Definition of NASH
Definition of NASH Nonalcoholic steatohepatitis (NASH) is the term used to describe the distinct clinical entity in which patients lack a history of significant alcohol consumption but have liver biopsy
More informationAASLD Immune tolerant phase HBV NAFLD diagnostic HCC
AASLD 2016 Immune tolerant phase HBV NAFLD diagnostic HCC Immune tolerant 3 Modified from Chan HLY and Wong VWS. Hepatitis B. In Zakim and Boyers s Hepatology 2012 2015 AMERICAN ASSOCIATION FOR THE S1T6UDY
More informationThe place of bariatric surgery in NASH: can we extend the indications? - No
The place of bariatric surgery in NASH: can we extend the indications? - No Nicolas Goossens Service de Gastroentérologie & Hépatologie Hôpitaux Universitaires de Genève Genève, Suisse How to extend the
More informationMETABOLIC SYNDROME AND HCV: FROM HCV
METABOLIC SYNDROME AND HCV: FROM THEORY TO PRACTICE HCV Steatosis Insulin resistance Arun J Sanyal M.D. Chairman, Div. of Gastroenterology, Hepatology and Nutrition Virginia Commonwealth University Richmond,
More informationNAFLD and NASH: The Not-So-New Kids on the Block
NAFLD and NASH: The Not-So-New Kids on the Block Mary E. Rinella, MD Associate Professor of Medicine Feinberg School of Medicine Northwestern University Chicago, Illinois This program is supported by an
More informationEmerging Challenges in Primary Care: Non-Alcoholic SteatoHepatitis (NASH): Identification & Evolving Treatment Strategies
Emerging Challenges in Primary Care: 2016 Non-Alcoholic SteatoHepatitis (NASH): Identification & Evolving Treatment Strategies Faculty Kalyan R. Bhamidimarri, MD, MPH Assistant Professor/ Transplant Hepatology
More informationStudy Design to Validate Biomarkers of Therapeutic Response in Pre-cirrhotic NASH
Study Design to Validate Biomarkers of Therapeutic Response in Pre-cirrhotic NASH Brent A. Neuschwander-Tetri, MD, FAASLD Professor of Internal Medicine Director, Division of Gastroenterology and Hepatology
More informationIn Search of New Biomarkers for Nonalcoholic Fatty Liver Disease
REVIEW In Search of New Biomarkers for Nonalcoholic Fatty Liver Disease Ting-Ting Chan, M.R.C.P., and Vincent Wai-Sun Wong, M.D. Nonalcoholic fatty liver disease (NAFLD) affects 15% to 40% of the general
More informationNAFLD - therapeutic intervention. CP Day Institute of Cellular Medicine Newcastle University UK
NAFLD - therapeutic intervention CP Day Institute of Cellular Medicine Newcastle University UK Therapy for NAFLD Why worry about NAFLD? Management strategy - who to treat? Therapies directed at features
More informationThe Liver for the Nonhepatologist
The Liver for the Nonhepatologist Michael R. Charlton, MBBS, FRCP Professor of Medicine University of Chicago Chicago, Illinois Overview Initial assessment of liver disease How do you diagnose cirrhosis?
More informationThe Liver for the Nonhepatologist
The Liver for the Nonhepatologist Michael R. Charlton, MBBS, FRCP Hepatology Director and Medical Director of Liver Transplantation Intermountain Medical Center Salt Lake City, Utah FORMATTED: 05-14-15
More informationBariatric Surgery and Liver Transplantation
Bariatric Surgery and Liver Transplantation Sammy Saab, MD, MPH, AGAF, FACG, FAASLD Professor of Medicine and Surgery Head, Outcomes Research in Hepatology David Geffen School of Medicine at UCLA Disclosures
More informationJoslin Diabetes Center Advances in Diabetes and Thyroid Disease 2013 Nonalcoholic Fatty Liver Disease: The Burgeoning Epidemic
NONALCOHOLIC STEATOHEPATITIS Sanjiv Chopra, M.D., MACP Professor of Medicine Faculty Dean for Continuing Education Harvard Medical School Senior Consultant in Hepatology Beth Israel Deaconess Medical Center
More informationNon-Alcoholic Fatty Liver Disease (NAFLD)
HEPATO-PANCREATO-BILIARY STOMACH CANCER PROGRAM Non-Alcoholic Fatty Liver Disease (NAFLD) Steatosis and Non-Alcoholic Steatohepatitis (NASH) Management Recommendations UCSF Fresno Department of Surgery
More informationWhen to Treat: Staging Liver Disease David L. Thomas, MD, MPH
When to Treat: Staging Liver Disease David L. Thomas, MD, MPH Professor of Medicine Johns Hopkins School of Medicine Disclosures Received royalties from UpToDate, Inc. Staging refers to the assessment
More informationA pathologist, a radiologist and a hepatologist walked into a bar
A pathologist, a radiologist and a hepatologist walked into a bar Brent A. Neuschwander-Tetri, MD, FAASLD Professor of Internal Medicine Director, Division of Gastroenterology and Hepatology Saint Louis
More information«STEATOSI EPATICA ED EPATOPATIE METABOLICHE» Ester Vanni Division of Gastroenterology University of Turin
«STEATOSI EPATICA ED EPATOPATIE METABOLICHE» Ester Vanni Division of Gastroenterology University of Turin OUTLINE NAFLD overview NAFLD and menarche NAFLD and pregnancy NAFLD and menopause Other metabolic
More informationNon-invasive diagnostic biomarkers
Non-invasive diagnostic biomarkers Liver Forum, November 12 th, 2015 Rohit Loomba, MD, MHSc Professor of Medicine (with tenure) Director, NAFLD Research Center, Division of Gastroenterology, Department
More informationTreatment of NASH: What Helps Beyond Weight Loss?
THE RED SECTION 821 see related editorial on page x Treatment of NASH: What Helps Beyond Weight Loss? Bubu A. Banini, MD, PhD1 and Arun J. Sanyal, MBBS, MD1 Am J Gastroenterol 2017; 112:821 824; doi: 10.1038/ajg.2017.83;
More informationINVESTOR PRESENTATION. November 16 th, 2015
INVESTOR PRESENTATION November 16 th, 2015 1 Disclaimer Important information and forward looking statements GENFIT IS A PUBLIC COMPANY LISTED ON EURONEXT PARIS (COMPARTMENT B) STOCK EXCHANGE SINCE APRIL
More informationNASH: WHAT YOU NEED TO KNOW
NASH: WHAT YOU NEED TO KNOW MARCELO KUGELMAS, MD, FACP SOUTH DENVER GASTROENTEROLOGY CENTER FOR DISEASES OF THE LIVER AND PANCREAS, SWEDISH MEDICAL CENTER CLINICAL ASSOCIATE PROFESSOR OF MEDICINE, UNIVERSITY
More informationOcaliva (obeticholic acid tablets)
Ocaliva (obeticholic acid tablets) Policy Number: 5.01.619 Last Review: 11/2018 Origination: 11/2016 Next Review: 11/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage
More informationHow to manage patients with NASH? Dr Raluca Pais Institute of Cardiometabolisme and Nutrition (ICAN) Hôpital Pitie Salpetrière, Paris
How to manage patients with NASH? Dr Raluca Pais Institute of Cardiometabolisme and Nutrition (ICAN) Hôpital Pitie Salpetrière, Paris CLINICAL CASE 1996. 54 years old female Department of Primary CV Prevention
More informationPathogenesis and Management of Non-Alcoholic Fatty Liver Disease
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/lipid-luminations/pathogenesis-management-non-alcoholic-fatty-liverdisease/8155/
More informationWhy to biopsy? Indications for liver biopsy in common medical liver diseases- how are they changing?
Why to biopsy? Indications for liver biopsy in common medical liver diseases- how are they changing? Stephen D Ryder Nottingham University Hospitals NHS Trust and Biomedical research Unit What are we currently
More informationUltrasound showing. Biopsies. Criteria for Dx of NASH. macrovesicular steatosis (zone III) Bright echogenic liver. Definition of NASH
Definition of NASH Nonalcoholic steatohepatitis (NASH) is the term used to describe the distinct clinical entity in which patients lack a history of significant alcohol consumption but have liver biopsy
More informationFaculty Disclosure. Objectives. Cirrhosis Management for the Family Physician 18/11/2014
Cirrhosis Management for the Family Physician Mang Ma, MD, FRCP Professor University of Alberta Faculty: Mang Ma Faculty Disclosure Relationships with commercial interests: Advisory Board: Merck, Gilead
More informationPreface: Nonalcoholic Fatty Liver Disease: An Expanding Health Care Epidemic
NASH and NAFLD Preface: Nonalcoholic Fatty Liver Disease: An Expanding Health Care Epidemic David E. Bernstein xiii Clinical and Economic Burden of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis
More informationWORKSHOP. How to manage patients with NASH? Pr Jérôme Boursier Angers, France
WORKSHOP How to manage patients with NASH? Pr Jérôme Boursier Angers, France 11th Paris Hepatology Conference January 16th, 2018 Clinical case Man Man63 63years yearsold, old,referred referredby byhis
More informationThe Diagnosis and Management of Nonalcoholic Fatty Liver Disease: Practice Guidance From the American Association for the Study of Liver Diseases
AMERICAN ASSOCIATION FOR THE STUDY OFLIVERD I S E ASES PRACTICE GUIDANCE HEPATOLOGY, VOL. 67, NO. 1, 2018 The Diagnosis and Management of Nonalcoholic Fatty Liver Disease: Practice Guidance From the American
More informationLiver 102: Injury and Healing
Liver 102: Injury and Healing Dawn Pease, MSN, RN, ANP-BC Brackenridge Specialty Clinics University Medical Center Brackenridge Austin, TX Seton Healthcare Family Liver 102 Outline Biochemical patterns
More informationDefining the gold standard in biomarker validation for NASH
Defining the gold standard in biomarker validation for NASH Arun J Sanyal M.D. Professor of Medicine, Physiology and Molecular Pathology Virginia Commonwealth University School of Medicine Conflicts of
More informationTherapeutic targets and the management of NASH
Therapeutic targets and the management of NASH Joo Hyun Sohn, MD. Professor of Medicine, College of Medicine, Hanyang University Division of Gastroenterology and Hepatology Hanyang University Guri Hospital
More informationNAFLD, NASH, and alcoholic liver disease
NAFLD, NASH, and alcoholic liver disease Jonathan Congeni MD NAFLD, NASH, and alcoholic liver disease Disease overview Epidemiology Pathogenesis Clinical features Labs and imaging Evaluation options Focus
More informationEvercore ISI Presentation- Madrigal
Evercore ISI Presentation- Madrigal Forward-Looking Statements Any statements, other than statements of historical facts, made in this presentation regarding our clinical studies and our research and development
More informationHHS Public Access Author manuscript Clin Gastroenterol Hepatol. Author manuscript; available in PMC 2016 April 13.
Relationship between changes in serum keratin 18 and changes in liver histology in children and adults with nonalcoholic fatty liver disease Raj Vuppalanchi 1, Ajay K. Jain 2, Ross Deppe 1, Katherine Yates
More informationEASL EASD EASO Clinical practice guidelines for the management of nonalcoholic fatty liver disease.
Commentary. EASL EASD EASO Clinical practice guidelines for the management of nonalcoholic fatty liver disease. Christopher D. Byrne 1,2, Giovanni Targher 3 1 Nutrition and Metabolism, Faculty of Medicine,
More informationHHS Public Access Author manuscript Hepatology. Author manuscript; available in PMC 2017 March 01.
Febuxostat-Induced Acute Liver Injury Matt Bohm, DO, Raj Vuppalanchi, MD, Naga Chalasani, MD, and Drug Induced Liver Injury Network (DILIN) Department of Medicine, Indiana University School of Medicine,
More informationSteatotic liver disease
Steatotic liver disease Fatty liver disease Prof. Dr. ANNE HOORENS Non-Neoplastic Liver Pathology December 8th 2018 Working Group of Digestive Pathology Belgian Society of Pathology OUTLINE NAFLD = Non-Alcoholic
More informationCriteria for Dx of NASH NONALCOHOLIC STEATOHEPATITIS. Liver Ultrasound Report. Presenter Disclosure Information. Definition of NASH
1 1:45 pm NASH: Burgeoning Epidemic SPEAKER Sanjiv Chopra, MD, MACP Presenter Disclosure Information The following relationships exist related to this presentation: Sanjiv Chopra, MD, MACP: No financial
More informationOral Testosterone (T) Non Alcoholic Steatohepatitis (NASH)
Oral Testosterone (T) Non Alcoholic Steatohepatitis (NASH) 1 LPCN 1144: Well Positioned for Success Unique Mechanism of Action with Compelling Clinical Signal Targeting Full Spectrum of NASH Pathogenesis
More information